# Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

> **NCT00697567** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 80 (actual)

## Conditions studied

- Prophylaxis Herpes Simplex

## Interventions

- **BIOLOGICAL:** Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant
- **BIOLOGICAL:** Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant

## Key facts

- **NCT ID:** NCT00697567
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1992-09
- **Primary completion:** 1997-12
- **Final completion:** 1997-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2008-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00697567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00697567, "Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00697567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*